A systematic review of treatment guidelines for metastatic colorectal cancer.
A systematic review of treatment guidelines for metastatic colorectal cancer.
复制标题
DOI：
10.1111/j.1463-1318.2011.02765.x
复制
发表时间：
2012-02
期刊：
影响因子：
--
通讯作者：
Sykes DP
中科院分区：
文献类型：
--
作者：
Edwards MS;Chadda SD;Zhao Z;Barber BL;Sykes DP
对转移性结直肠癌（mCRC）治疗指南进行了系统回顾，以评估这些指南中单克隆抗体治疗的建议。通过MEDLINE、MEDLINE In Process、EMBASE和Cochrane Library的电子检索检索到相关论文；通过人工检索参考书目；以及通过互联网搜索。共确定了57项有关准则，其中32项通过电子数据库检索，25项通过网站检索。大多数指南是在2004年至2010年间发布的。发布指南最多的国家是美国（12份），其次是英国（10份）、加拿大（8份）、法国（8份）、德国（3份）、澳大利亚（2份）、西班牙（2份）和意大利（1份）。此外，还确定了8项欧洲准则和3项国际准则。由于单克隆抗体治疗mCRC直到2004年才被引入，2004年至2006年出版的指南中没有对单克隆抗体治疗提出明确的建议。单克隆抗体治疗的建议首次出现在2007年，并随着更多数据的获得而发展。最新的国际、欧洲和美国指南推荐联合化疗加单克隆抗体用于一线治疗mCRC。二线治疗取决于使用的一线治疗方案。对于化疗耐药的mCRC，西妥昔单抗或帕尼单抗被推荐作为野生型KRAS肿瘤患者的单药治疗。该研究表明，最近的治疗指南已经认识到单克隆抗体在mCRC管理中的作用，并且治疗指南应该及时更新以反映最新的可用数据。
A systematic review of treatment guidelines for metastatic colorectal cancer (mCRC) was performed to assess recommendations for monoclonal antibody therapy in these guidelines. Relevant papers were identified through electronic searches of MEDLINE, MEDLINE In Process, EMBASE and the Cochrane Library; through manual searches of reference lists; and by searching the Internet. A total of 57 relevant guidelines were identified, 32 through electronic database searches and 25 through the website searches. The majority of guidelines were published between 2004 and 2010. The country publishing the most guidelines was the USA (12), followed by the UK (10), Canada (eight), France (eight), Germany (three), Australia (two), Spain (two) and Italy (one). In addition, eight European and three international guidelines were identified. As monoclonal antibody therapy for mCRC was not introduced until 2004, no firm recommendations for monoclonal antibody therapy were made in guidelines published between 2004 and 2006. Recommendations for monoclonal antibody therapy first appeared in 2007 and evolved as more data became available. The most recent international, European and US guidelines recommend combination chemotherapy with the addition of a monoclonal antibody for the first-line treatment of mCRC. Second-line treatment depends on the first-line regimen used. For chemoresistant mCRC, cetuximab or panitumumab are recommended as monotherapy in patients with wild-type KRAS tumours. The study indicates that recent treatment guidelines have recognized the role of monoclonal antibodies in the management of mCRC, and that treatment guidelines should be updated in a timely manner to reflect the most recently available data.
登录
查看更多内容
影响因子：
3.4
作者：
Abad, A.;Figueras, J.;Aranda, E.
通讯作者：
Aranda, E.
影响因子：
3.7
作者：
Bartlett, David L.;Berlin, Jordan;Venook, Alan P.
通讯作者：
Venook, Alan P.
影响因子：
50.5
作者：
Glimelius, B.;Oliveira, J.
通讯作者：
Oliveira, J.
影响因子：
158.5
作者：
Hurwitz, H;Fehrenbacher, L;Kabbinavar, F
通讯作者：
Kabbinavar, F
影响因子：
45.3
作者：
Douillard, Jean-Yves;Siena, Salvatore;Gansert, Jennifer
通讯作者：
Gansert, Jennifer